Stephen Collins Email

CMO . Xalud Therapeutics

Current Roles

Employees:
43
Revenue:
$6.7M
About
Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. Xalud's lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10 to addresses pathologic inflammation and pain.
Xalud Therapeutics Address
40 West 57th Street
New York , NY
United States
Xalud Therapeutics Email

Past Companies

Vetana Animal HealthExecutive Chairman
Xalud Therapeutics, Inc.Strategic Advisor
Xalud Therapeutics, Inc.Member Board Of Directors

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.